Neurofilaments as Emerging Biomarkers of Neuroaxonal Damage to Differentiate Behavioral Frontotemporal Dementia from Primary Psychiatric Disorders: A Systematic Review.
Vincent DavyJulien DumurgierAurore FayosseClaire PaquetEmmanuel CognatPublished in: Diagnostics (Basel, Switzerland) (2021)
The behavioral variant of frontotemporal dementia (bvFTD) is a clinical syndrome resulting from various causes of neuronal demises associated with frontotemporal lobar degeneration. Symptoms include behavioral and personality changes, social cognitive impairment, and executive function deficits. There is a significant clinical overlap between this syndrome and various primary psychiatric disorders (PPD). Structural and functional neuroimaging are considered helpful to support the diagnosis of bvFTD, but their sensitivity and specificity remain imperfect. There is growing evidence concerning the potential of neurofilaments as biomarkers reflecting axonal and neuronal lesions. Ultrasensitive analytic platforms have recently enabled neurofilament light chains' (NfL) detection not only from cerebrospinal fluid but also from peripheral blood samples in FTD patients. In this short review, we present recent advances and perspectives for the use of NfL assessments as biomarkers of neuroaxonal damage to differentiate bvFTD from primary psychiatric disorders.
Keyphrases
- cerebrospinal fluid
- peripheral blood
- cognitive impairment
- end stage renal disease
- chronic kidney disease
- oxidative stress
- ejection fraction
- newly diagnosed
- spinal cord injury
- traumatic brain injury
- healthcare
- gold nanoparticles
- mental health
- peritoneal dialysis
- risk assessment
- cerebral ischemia
- quantum dots
- sleep quality
- peripheral nerve